Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 4Uterine Cervical Dysplasia 3Papilloma 1Neoplasms, Squamous Cell 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Neoplasms 1

Interventions

Gemcitabine 57Paclitaxel 50Cyclophosphamide 45pembrolizumab 44Carboplatin 41Bevacizumab 38Cisplatin 33Docetaxel 31Fluorouracil 30Nivolumab 29Capecitabine 29Pemetrexed 24Irinotecan 24Oxaliplatin 23Dexamethasone 23Ipilimumab 22Leucovorin 21Radiotherapy 20Sorafenib 19Doxorubicin 19Everolimus 18Cetuximab 18fludarabine 17Albumin-Bound Paclitaxel 17trametinib 15Sunitinib 15Rituximab 15Erlotinib Hydrochloride 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms × Colposcopy × Clear all
NCT01234480 2023-05-16

Intended Use Study of the BD SurePath Plusâ„¢ Pap

Becton, Dickinson and Company

Terminated
5,859 enrolled 4 charts
Gynecologic

Uterine Cervical Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡